Brown Adipose Tissue Activity and Energy Metabolism in Cachexia
- Conditions
- CachexiaNeoplasmsPulmonary Disease, Chronic ObstructivePancreatic Neoplasms
- Registration Number
- NCT02500004
- Lead Sponsor
- Maastricht University Medical Center
- Brief Summary
To study BAT activity and energy metabolism in patients with cachexia induced by cancer or chronic disease.
- Detailed Description
This is a prospective, cross-sectional study to determine BAT activity in cachectic patients with pancreatic or non-small cell lung cancer, and in cachectic patients with chronic obstructive pulmonary disease (COPD), and compare results with healthy individuals and non-cachectic COPD patients, matched for age and BMI.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 16
- Pancreatic cancer patients, or NSCLC cancer patients, or COPD patients
- The diagnostic criterion for cachexia is unintentional weight loss more than 5% over the past 6 months or more than 2% in individuals with a body-mass index < 20 kg/m2 and muscle wasting assessed by DXA;
- Age ≥ 30 years;
- Gender: male and female;
- Caucasians.
- Uncontrolled Diabetes Mellitus;
- Patients with severe clotting disorder;
- Patients with an active second malignancy;
- Psychological unstable persons presumed unfit to perform the measurements, including claustrophobia;
- Persons unable to lie or sit still for 1-2 hours;
- Oxygen therapy;
- Pregnant subjects;Subjects unable to undergo MRI (e.g. pacemaker; neurostimulator; implantable cardioverter-defibrillator (ICD) or leads; Foley bladder catheter; medication pump; cochlear or hearing implant; tattoos or other items that cannot be removed and include metal parts (for instance from operations in the past); metal splinter in the eye; vascular clips; denture, which contains magnets);
- Subjects that received high doses of radiotherapeutic radiation of the neck and/or upper chest in their medical history;
- Persons that received cervical or thoracic sympathectomy or have a nerve dysfunction which is likely to influence sympathetic nerves;
- The use of medication that influences the sympathetic nerve system: ß-blockers, α-blockers, central anti-hypertensives, certain anti-depression drugs (MAO inhibitors, tricyclic anti-depressives), reserpine, cocaine, calciumblockers, labetalol, and certain tranquillizers (fenothiazines).
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Brown adipose tissue (BAT) activity measured by PET(-MRI) participants will be followed for 2 weeks The main endpoint of this study is BAT volume and intensity of activity in Standard Uptake Value (SUV) in the presence of cancer cachexia, COPD cachexia, and compared to non-cachectic COPD patients and healthy individuals, as assessed by 18F-fluoro-deoxyglucose (18F-FDG) PET-MRI scanning.
- Secondary Outcome Measures
Name Time Method Hormonal status measured in blood participants will be followed for 2 weeks Resting metabolic rate measured by REE participants will be followed for 2 weeks Metabolic gene expression in WAT measured by biopsy of subcutaneous fat participants will be followed for 2 weeks Total energy metabolism measured by resting energy expenditure (REE) and doubly labeled water participants will be followed for 2 weeks Systemic inflammatory status measured in blood participants will be followed for 2 weeks Lean tissue mass measured by MRI, DXA, and doubly labeled water participants will be followed for 2 weeks Detailed body composition phenotyping of cachexia by (PET-)MRI to compare with commonly applied clinical measures (D2O and DXA)
Fat tissue mass measured by MRI, DXA, and doubly labeled water participants will be followed for 2 weeks Detailed body composition phenotyping of cachexia by (PET-)MRI to compare with commonly applied clinical measures (D2O and DXA)
Trial Locations
- Locations (1)
Maastricht UMC+
🇳🇱Maastricht, Netherlands
Maastricht UMC+🇳🇱Maastricht, Netherlands